aibioFirst Tracks Biotherapeutics agrees to sell 6,106,870 shares at $32.75, about $200 million
Tickers TRAX
The company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.
Key facts
- Company
- First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX)
- News type
- Financings
- Primary source
- First Tracks Biotherapeutics, Inc. 8-K (2026-10-15)
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) said on October 15, 2026 that it signed a securities purchase agreement to sell 6,106,870 shares of common stock to a limited group of institutional investors in a private placement at $32.75 per share. The company expects approximately $200 million in gross proceeds before deducting placement agent fees and other expenses.
Investors include Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners and Vestal Point Capital, along with other institutional investors and mutual funds. Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities were placement agents.
First Tracks plans to use the proceeds for general corporate purposes, including clinical development of ANB033, a CD122 antagonist.
In a filing dated October 20, 2026, the company said it closed the placement on October 19, 2026. At closing it signed a registration rights agreement with the investors. The agreement requires First Tracks to file or confidentially submit a registration statement covering resale of the shares as promptly as reasonably practicable, and no later than 30 days after the closing date. The shares were sold without registration under the Securities Act of 1933.